...
search icon
sln-img

Silence Therapeutics PLC, Common Stock

SLN

NMQ

$2.89

+$0.47

(19.42%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$222.85M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
275.87K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.37 L
$24.38 H
$2.89

About Silence Therapeutics PLC, Common Stock

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSLNSectorS&P500
1-Week Return-12.95%-0.3%-1.65%
1-Month Return-33.1%-3.53%-3.93%
3-Month Return-59.81%4.86%-4.03%
6-Month Return-84.29%-5.62%-1.34%
1-Year Return-86.39%0.08%8.15%
3-Year Return-84.54%5.39%22.85%
5-Year Return-85.18%64.78%122.87%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue5.48M12.41M17.50M25.38M43.26M[{"date":"2020-12-31","value":12.67,"profit":true},{"date":"2021-12-31","value":28.7,"profit":true},{"date":"2022-12-31","value":40.46,"profit":true},{"date":"2023-12-31","value":58.66,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue3.76M7.46M10.88M10.32M11.81M[{"date":"2020-12-31","value":31.85,"profit":true},{"date":"2021-12-31","value":63.13,"profit":true},{"date":"2022-12-31","value":92.13,"profit":true},{"date":"2023-12-31","value":87.37,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit1.72M4.96M6.62M15.06M31.45M[{"date":"2020-12-31","value":5.46,"profit":true},{"date":"2021-12-31","value":15.77,"profit":true},{"date":"2022-12-31","value":21.05,"profit":true},{"date":"2023-12-31","value":47.88,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin31.34%39.94%37.83%59.34%72.70%[{"date":"2020-12-31","value":43.11,"profit":true},{"date":"2021-12-31","value":54.94,"profit":true},{"date":"2022-12-31","value":52.04,"profit":true},{"date":"2023-12-31","value":81.62,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses37.56M50.77M55.21M64.66M94.77M[{"date":"2020-12-31","value":39.64,"profit":true},{"date":"2021-12-31","value":53.58,"profit":true},{"date":"2022-12-31","value":58.26,"profit":true},{"date":"2023-12-31","value":68.23,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(35.85M)(45.81M)(48.59M)(49.60M)(63.32M)[{"date":"2020-12-31","value":-3584700000,"profit":false},{"date":"2021-12-31","value":-4581400000,"profit":false},{"date":"2022-12-31","value":-4859300000,"profit":false},{"date":"2023-12-31","value":-4960400000,"profit":false},{"date":"2024-12-31","value":-6331900000,"profit":false}]
Total Non-Operating Income/Expense1.53M(40.00K)1.40M706.00K23.33M[{"date":"2020-12-31","value":6.58,"profit":true},{"date":"2021-12-31","value":-0.17,"profit":false},{"date":"2022-12-31","value":6.02,"profit":true},{"date":"2023-12-31","value":3.03,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(36.04M)(45.86M)(47.37M)(50.31M)(44.46M)[{"date":"2020-12-31","value":-3604100000,"profit":false},{"date":"2021-12-31","value":-4585600000,"profit":false},{"date":"2022-12-31","value":-4736800000,"profit":false},{"date":"2023-12-31","value":-5031000000,"profit":false},{"date":"2024-12-31","value":-4446400000,"profit":false}]
Income Taxes(3.49M)(6.45M)(6.88M)(7.04M)845.00K[{"date":"2020-12-31","value":-413.49,"profit":false},{"date":"2021-12-31","value":-762.84,"profit":false},{"date":"2022-12-31","value":-814.08,"profit":false},{"date":"2023-12-31","value":-833.49,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(32.55M)(39.41M)(40.49M)(43.27M)(45.31M)[{"date":"2020-12-31","value":-3254700000,"profit":false},{"date":"2021-12-31","value":-3941000000,"profit":false},{"date":"2022-12-31","value":-4048900000,"profit":false},{"date":"2023-12-31","value":-4326700000,"profit":false},{"date":"2024-12-31","value":-4530900000,"profit":false}]
Income From Continuous Operations(22.06M)(39.41M)(40.49M)(43.27M)(45.31M)[{"date":"2020-12-31","value":-2205800000,"profit":false},{"date":"2021-12-31","value":-3941000000,"profit":false},{"date":"2022-12-31","value":-4048900000,"profit":false},{"date":"2023-12-31","value":-4326700000,"profit":false},{"date":"2024-12-31","value":-4530900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(32.55M)(39.41M)(40.49M)(43.27M)(45.31M)[{"date":"2020-12-31","value":-3254700000,"profit":false},{"date":"2021-12-31","value":-3941000000,"profit":false},{"date":"2022-12-31","value":-4048900000,"profit":false},{"date":"2023-12-31","value":-4326700000,"profit":false},{"date":"2024-12-31","value":-4530900000,"profit":false}]
EPS (Diluted)(0.56)(1.16)0.11(0.76)-[{"date":"2020-12-31","value":-504.86,"profit":false},{"date":"2021-12-31","value":-1044.28,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-685.96,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SLN
Cash Ratio 8.76
Current Ratio 11.14

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SLN
ROA (LTM) -27.27%
ROE (LTM) -102.80%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SLN
Debt Ratio Lower is generally better. Negative is bad. 0.34
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.66

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SLN
Trailing PE NM
Forward PE NM
P/S (TTM) 3.16
P/B 1.00
Price/FCF NM
EV/R 0.30
EV/Ebitda NM

FAQs

What is Silence Therapeutics PLC share price today?

Silence Therapeutics PLC (SLN) share price today is $2.89

Can Indians buy Silence Therapeutics PLC shares?

Yes, Indians can buy shares of Silence Therapeutics PLC (SLN) on Vested. To buy Silence Therapeutics PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Silence Therapeutics PLC be purchased?

Yes, you can purchase fractional shares of Silence Therapeutics PLC (SLN) via the Vested app. You can start investing in Silence Therapeutics PLC (SLN) with a minimum investment of $1.

How to invest in Silence Therapeutics PLC shares from India?

You can invest in shares of Silence Therapeutics PLC (SLN) via Vested in three simple steps:

  • Click on Sign Up or Invest in SLN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Silence Therapeutics PLC shares
What is Silence Therapeutics PLC 52-week high and low stock price?

The 52-week high price of Silence Therapeutics PLC (SLN) is $24.38. The 52-week low price of Silence Therapeutics PLC (SLN) is $2.37.

What is Silence Therapeutics PLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Silence Therapeutics PLC (SLN) is 1.00

What is the Market Cap of Silence Therapeutics PLC?

The market capitalization of Silence Therapeutics PLC (SLN) is $222.85M

What is Silence Therapeutics PLC’s stock symbol?

The stock symbol (or ticker) of Silence Therapeutics PLC is SLN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top